SLC40A1 and breast carcinoma: Low ferroportin expression has been linked to increased metastatic potential and worse clinical outcomes in breast cancer patients[7,8], Beyond its role in cellular metabolism, iron dysregulation actively contributes to the remodeling of the breast cancer tumor microenvironment.